A functional polymorphism of TGFBR2 is associated with risk of breast cancer with ER+, PR+, ER+PR+ and HER2- expression in women

Zhang,Mei; Guo,Ling-Ling; Cheng,Zhongqin; Liu,Reng-Yun; Lu,Yufeng; Qian,Qian; Lei,Zhe; Zhang,Hong-Tao

doi:10.3892/ol.2011.312

A functional polymorphism of TGFBR2 is associated with risk of breast cancer with ER+, PR+, ER+PR+ and HER2- expression in women

Authors:
- Mei Zhang
- Ling-Ling Guo
- Zhongqin Cheng
- Reng-Yun Liu
- Yufeng Lu
- Qian Qian
- Zhe Lei
- Hong-Tao Zhang
View Affiliations

Affiliations: Department of Pathology, School of Medicine, Medical College of Soochow University, Sino-Singapore Industrial Park, Suzhou 215123, P.R. China, Department of Pathology, School of Medicine, Medical College of Soochow University, Sino-Singapore Industrial Park, Suzhou 215123, P.R. China, Soochow University Laboratory of Cancer Molecular Genetics, Medical College of Soochow University, Sino-Singapore Industrial Park, Suzhou 215123, P.R. China, Department of Oncology, School of Medicine, Medical College of Soochow University, Sino-Singapore Industrial Park, Suzhou 215123, P.R. China, Soochow University Laboratory of Cancer Molecular Genetics, Medical College of Soochow University, Sino-Singapore Industrial Park, Suzhou 215123, P.R. China
Published online on: May 13, 2011 https://doi.org/10.3892/ol.2011.312
Pages: 653-658

Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )

Metrics: Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )

Cited By (CrossRef): 0 citations Loading Articles...

Abstract

Little is known about the correlation between TGFBR2 G-875A and breast cancer risk. Moreover, the associations of the expression of estrogen receptor (ER), progesterone receptor (PR) and human epidermal growth factor receptor-2 (HER2) in breast cancer tissues with the TGFB1 C-509T, T+29C and TGFBR2 G-875A polymorphisms remain to be determined. In this study, we genotyped for TGFB1 C-509T, T+29C and TGFBR2 G-875A in fresh surgically resected tissues (n=82) and archived paraffin-embedded specimens (n=88) from 170 patients with breast cancer, as well as peripheral blood samples from 178 cancer‑free female individuals. Evaluation of ER, PR and HER2 expression was performed using immunohistochemical staining. Logistic regression analysis was carried out to determine the risk of breast cancer by calculating the odds ratios (ORs) and their 95% confidence intervals (CIs). As a result, no difference was observed in the TGFB1 C-509T, T+29C genotype and allele frequencies between patients and controls. However, the frequency of the TGFBR2 -875A allele was marginally higher in cancer-free female individuals than that of women with breast cancer (24.2 vs. 17.9%, P=0.05). Notably, when stratification was performed by ER, PR and HER2 expression, the TGFBR2 -875A allele was found to correlate significantly to a decreased risk of breast cancer with ER+ (OR=0.57, 95% CI 0.35-0.92), PR+ (OR=0.54, 95% CI 0.34-0.88), ER+PR+ (OR=0.55, 95% CI 0.33-0.92) and HER2- (OR=0.55, 95% CI 0.34-0.88) under a dominant genetic model. In conclusion, this is the first study to suggest that the TGFBR2 -875A allele modifies predisposition to breast cancer with an expression of ER+, PR+, ER+PR+ and HER2-.

View Figures

View References

1	Ziegler RG, Anderson WF and Mh G: Increasing breast cancer incidence in China: the numbers add up. JNCI. 100:1339–1341. 2008. View Article : Google Scholar : PubMed/NCBI
2	Linos E, Rosner BA and Linos K: Effects of reproductive and demographic changes on breast cancer incidence in China: a modeling analysis. JNCI. 100:1352–1359. 2008. View Article : Google Scholar : PubMed/NCBI
3	Massague J and Chen YG: Controlling TGF-beta signaling. Genes Dev. 14:627–644. 2000.
4	Gobbi H, Arteaga CL, Jensen RA, Simpson JF, Dupont WD, Olson SJ, Schuyler PA, Plummer WD Jr and Page DL: Loss of expression of transforming growth factor beta type II receptor correlates with high tumour grade in human breast in situ and invasive carcinomas. Histopathology. 36:168–177. 2000. View Article : Google Scholar : PubMed/NCBI
5	Gobbi H, Dupont WD, Simpson JF, Plummer WD Jr, Schuyler PA, Olson SJ, Arteaga CL and Page DL: Transforming growth factor-beta and breast cancer risk in women with mammary epithelial hyperplasia. J Natl Cancer Inst. 91:2096–2101. 1999. View Article : Google Scholar : PubMed/NCBI
6	Daniel CW and Robinson SD: Regulation of mammary growth and function by TGF-beta. Mol Reprod Dev. 32:145–151. 1992. View Article : Google Scholar : PubMed/NCBI
7	Barcellos-Hoff MH and Ewan KB: Transforming growth factor-beta and breast cancer: mammary gland development. Breast Cancer Res. 2:92–99. 2000. View Article : Google Scholar : PubMed/NCBI
8	White RL: Tumor suppressing pathways. Cell. 92:591–592. 1998. View Article : Google Scholar
9	Cambien F, Ricard S, Troesch A, Mallet C, Generenaz L, Evans A, Arveiler D, Luc G, Ruidavets JB and Poirier O: Polymorphisms of the transforming growth factor-beta 1 gene in relation to myocardial infarction and blood pressure. The Etude Cas-Temoin de l’Infarctus du Myocarde (ECTIM) Study. Hypertension. 28:881–887. 1996.PubMed/NCBI
10	Seijo ER, Song H, Lynch MA, Jennings R, Qong X, Lazaridis E, Muro-Cacho C, Weghorst CM and Munoz-Antonia T: Identification of genetic alterations in the TGFbeta type II receptor gene promoter. Mutat Res. 483:19–26. 2001. View Article : Google Scholar : PubMed/NCBI
11	Zhang Y, Liu B, Jin M, Ni Q, Liang X, Ma X, Yao K, Li Q and Chen K: Genetic polymorphisms of transforming growth factor-beta1 and its receptors and colorectal cancer susceptibility: a population-based case-control study in China. Cancer Lett. 275:102–108. 2009. View Article : Google Scholar
12	Dunning AM, Ellis PD, McBride S, et al: A transforming growth factorbeta1 signal peptide variant increases secretion in vitro and is associated with increased incidence of invasive breast cancer. Cancer Res. 63:2610–2615. 2003.
13	Onitilo AA, Engel JM, Greenlee RT and Mukesh BN: Breast cancer subtypes based on ER/PR and Her2 expression: comparison of clinicopathologic features and survival. Clin Med Res. 7:4–13. 2009. View Article : Google Scholar : PubMed/NCBI
14	Kaklamani VG, Baddi L, Liu J, et al: Combined genetic assessment of transforming growth factor-beta signaling pathway variants may predict breast cancer risk. Cancer Res. 65:3454–3461. 2005.PubMed/NCBI
15	Paiva CE, Drigo SA, Rosa FE, Moraes Neto FA, Caldeira JR, Soares FA, Domingues MA and Rogatto SR: Absence of transforming growth factor-beta type II receptor is associated with poorer prognosis in HER2-negative breast tumours. Ann Oncol. 21:734–740. 2010. View Article : Google Scholar : PubMed/NCBI
16	Banerjee SK, Makdisi WF, Weston AP, Mitchell SM and Campbell DR: Microwave-based DNA extraction from paraffin-embedded tissue for PCR amplification. Biotechniques. 18:768–770. 772–763. 1995.PubMed/NCBI
17	Sato Y, Sugie R, Tsuchiya B, Kameya T, Natori M and Mukai K: Comparison of the DNA extraction methods for polymerase chain reaction amplification from formalin-fixed and paraffin-embedded tissues. Diagn Mol Pathol. 10:265–271. 2001. View Article : Google Scholar : PubMed/NCBI
18	Qi X, Zhang F, Yang X, Fan L, Zhang Y, Chen L, Zhou Y, Chen X, Zhong L and Jiang J: Transforming growth factor-beta1 polymorphisms and breast cancer risk: a meta-analysis based on 27 case-control studies. Breast Cancer Res Treat. 122:273–279. 2010. View Article : Google Scholar : PubMed/NCBI
19	Hishida A, Iwata H, Hamajima N, Matsuo K, Mizutani M, Iwase T, Miura S, Emi N, Hirose K and Tajima K: Transforming growth factor B1 T29C polymorphism and breast cancer risk in Japanese women. Breast Cancer. 10:63–69. 2003. View Article : Google Scholar : PubMed/NCBI
20	Cox DG, Penney K, Guo Q, Hankinson SE and Hunter DJ: TGFB1 and TGFBR1 polymorphisms and breast cancer risk in the Nurses’ Health Study. BMC Cancer. 7:1752007.PubMed/NCBI
21	Jin Q, Hemminki K, Grzybowska E, Klaes R, Soderberg M, Zientek H, Rogozinska-Szczepka J, Utracka-Hutka B, Pamula J, Pekala W and Forsti A: Polymorphisms and haplotype structures in genes for transforming growth factor beta1 and its receptors in familial and unselected breast cancers. Int J Cancer. 112:94–99. 2004. View Article : Google Scholar : PubMed/NCBI
22	Jin G, Wang L, Chen W, Hu Z, Zhou Y, Tan Y, Wang J, Hua Z, Ding W, Shen J, Zhang Z, Wang X, Xu Y and Shen H: Variant alleles of TGFB1 and TGFBR2 are associated with a decreased risk of gastric cancer in a Chinese population. Int J Cancer. 120:1330–1335. 2007. View Article : Google Scholar : PubMed/NCBI
23	Jin G, Deng Y, Miao R, Hu Z, Zhou Y, Tan Y, Wang J, Hua Z, Ding W, Wang L, Chen W, Shen J, Wang X, Xu Y and Shen H: TGFB1 and TGFBR2 functional polymorphisms and risk of esophageal squamous cell carcinoma: a case-control analysis in a Chinese population. J Cancer Res Clin Oncol. 134:345–351. 2008. View Article : Google Scholar : PubMed/NCBI
24	Knabbe C, Lippman ME, Wakefield LM, Flanders KC, Kasid A, Derynck R and Dickson RB: Evidence that transforming growth factor-beta is a hormonally regulated negative growth factor in human breast cancer cells. Cell. 48:417–428. 1987. View Article : Google Scholar : PubMed/NCBI
25	Wrana JL, Attisano L, Wieser R, Ventura F and Massague J: Mechanism of activation of the TGF-beta receptor. Nature. 370:341–347. 1994. View Article : Google Scholar : PubMed/NCBI
26	Buck M, von der Fecht J and Knabbe C: Antiestrogenic regulation of transforming growth factor beta receptors I and II in human breast cancer cells. Ann NY Acad Sci. 963:140–143. 2002. View Article : Google Scholar : PubMed/NCBI
27	Arteaga CL, Tandon AK, von Hoff DD and Osborne CK: Transforming growth factor beta: potential autocrine growth inhibitor of estrogen receptor-negative human breast cancer cells. Cancer Res. 48:3898–3904. 1988.
28	Kalkhoven E, Roelen BA, de Winter JP, Mummery CL, van den Eijnden-van Raaij AJ, van der Saag PT and van der Burg B: Resistance to transforming growth factor beta and activin due to reduced receptor expression in human breast tumor cell lines. Cell Growth Differ. 6:1151–1161. 1995.PubMed/NCBI